{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010419","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.191604+00:00","generated_at":"2026-06-04T14:22:18.083917+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Enveric signs non-binding term sheets for out-licensing joint disease compounds; up to $82M in milestones","bullets":["Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).","Pharma license potential milestones up to ~$61M; non-pharma up to ~$21M; combined up to ~$82M.","Royalty rates: pharma 2.5%-10%, non-pharma 0.25%-7% on future sales; licensee funds all development.","CEO Joseph Tucker highlights second company to license Enveric assets; definitive agreements remain to be negotiated.","Enveric focuses on neuroplastogenic therapeutics; out-licensing diversifies revenue from its asset portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010419","json":"https://secwatch.observer/filing/0001493152-24-010419.json","markdown":"https://secwatch.observer/filing/0001493152-24-010419.md","text":"https://secwatch.observer/filing/0001493152-24-010419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224010419/0001493152-24-010419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224010419/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:22:18.083917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}